The company said that it expects 2026 net sales growth of 1-2% now, previously estimated at atleast 5%. ・The company pinned the lowered guidance on sustained caution among U.S. Life Sciences customers ...
Hosted on MSN
Qiagen cuts 2026 outlook as TB test demand slumps
Qiagen has lowered its 2026 sales growth forecast to 1–2% from at least 5%, citing weak demand for its QuantiFERON tuberculosis test, cautious U.S. Life Sciences spending, and geopolitical uncertainty ...
New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with tuberculin ...
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results